8-K: AirSculpt Technologies Reports Mixed Q2 Results, Revises Full-Year Guidance and Announces CEO Transition

AirSculpt Technologies announced a decrease in revenue and profitability for the second quarter of 2024, leading to a revised full-year outlook and a change in CEO.

Summary

• AirSculpt Technologies reported a challenging second quarter of 2024, with revenue declining by 8.4% to $51.0 million compared to $55.7 million in the same period last year.
• The company experienced a net loss of $3.2 million for the quarter, a significant drop from the $1.8 million net income in the second quarter of 2023.
• Adjusted EBITDA also decreased to $6.9 million, down from $14.6 million in the prior year's second quarter.
• Case volume decreased by 5.7% to 3,949 cases in the second quarter of 2024.
• For the first six months of 2024, revenue declined by 2.8% to $98.6 million, and adjusted EBITDA was $14.2 million, compared to $24.1 million in the same period of 2023.
• The company has revised its full-year 2024 revenue guidance to approximately $180 to $190 million and adjusted EBITDA guidance to approximately $23 to $28 million.
• AirSculpt plans to open five new centers in the second half of 2024.
• The company had $9.9 million in cash and cash equivalents and $5.0 million of borrowing capacity as of June 30, 2024.
• Operating cash flow for the first six months of 2024 was $6.8 million, compared to $18.5 million for the same period in 2023.
• Todd Magazine has resigned as CEO and a member of the Board of Directors, with Dennis Dean, the CFO, stepping in as Interim CEO.

Sentiment

Score: 4

Explanation: The document conveys a negative sentiment due to the significant decline in financial performance, revised guidance, and CEO transition. While there are some positive points, the overall tone is cautious and indicates challenges ahead.

Positives

• De novo locations opened in 2023 performed ahead of expectations, indicating strong demand for AirSculpt's procedures.
• The company has a strong and durable balance sheet.
• AirSculpt has provided more than 60,000 positive patient experiences since its founding.
• The company has $9.9 million in cash and cash equivalents and $5.0 million of borrowing capacity.

Negatives

• Second quarter revenue declined by 8.4% year-over-year.
• The company experienced a net loss of $3.2 million in the second quarter, a significant decrease from the net income of $1.8 million in the same period last year.
• Adjusted EBITDA decreased to $6.9 million in the second quarter, down from $14.6 million in the prior year.
• Case volume decreased by 5.7% in the second quarter.
• The company has revised its full-year revenue and adjusted EBITDA guidance downwards.
• Operating cash flow decreased significantly to $6.8 million for the first six months of 2024, compared to $18.5 million in the same period of 2023.
• Same-center case growth declined by 14.0% for the three months ended June 30, 2024.

Risks

• The company faces challenges due to a difficult consumer spending environment.
• Brand awareness spending has a longer case conversion cycle, impacting profitability.
• There is increased competition in the weight loss and obesity solutions market, including the rise of weight-loss drugs.
• The company is exposed to risks related to opening and operating new centers, including rising interest rates and inflation.
• There are risks associated with shortages or quality control issues with third-party manufacturers or suppliers.
• The company faces competition for surgeons and potential litigation or medical malpractice claims.
• Changes in laws governing the corporate practice of medicine or fee-splitting could impact the business.
• Macroeconomic conditions, including inflation and the threat of recession, pose risks to the company's performance.
• Business disruptions from war, pandemic, terrorist acts, or political unrest could affect operations.

Future Outlook

The company has revised its full-year 2024 revenue guidance to approximately $180 to $190 million and adjusted EBITDA guidance to approximately $23 to $28 million. They plan to open five new centers in the second half of 2024.

Management Comments

• Dennis Dean, Interim CEO, stated he was disappointed with the second quarter results and is eager to improve the foundation for future growth.
• Mr. Dean noted that revenue performance reflected a challenging consumer spending environment and profitability was pressured by brand awareness spend.
• Mr. Dean highlighted that de novo locations opened in 2023 performed ahead of expectations.
• The company's near-term priorities are to return to its core business, reduce costs, stabilize revenue, and maintain a strong balance sheet.

Industry Context

The announcement comes at a time when the aesthetic and body contouring industry is facing increased competition, particularly from the growing popularity of weight-loss drugs. This is impacting AirSculpt's case volumes and revenue, requiring the company to adjust its strategies and financial outlook.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the decline in AirSculpt's case volume and revenue suggests they are underperforming compared to some industry benchmarks.
• The company's adjusted EBITDA margin of 13.5% for the second quarter is significantly lower than the 26.2% reported in the same period last year, indicating a potential struggle with profitability compared to industry averages.
• The revised full-year guidance suggests a more conservative outlook compared to previous expectations, which may be a reflection of broader industry trends or specific challenges faced by AirSculpt.
• Companies like InMode and Cutera, which also operate in the aesthetic device and procedure market, have been reporting varying results, with some showing growth while others face similar challenges, making it difficult to draw a direct comparison without specific data.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decline in financial performance and the revised guidance, potentially leading to a decrease in share price.
• Employees may experience uncertainty due to the CEO transition and the company's focus on cost reduction.
• Customers may be impacted by any changes in service or pricing as the company adjusts its strategies.
• Suppliers and creditors may be affected by the company's revised financial outlook and cost-cutting measures.

Next Steps

• The company plans to focus on returning to its core business, reducing costs, and stabilizing revenue.
• AirSculpt will open five new centers in the second half of 2024.
• The Board of Directors will conduct a search for a permanent CEO.

Key Dates

Keywords

AirSculpt, body contouring, revenue, EBITDA, net loss, case volume, financial results, guidance, CEO, interim CEO